{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:27:35Z","timestamp":1782858455215,"version":"3.54.5"},"reference-count":62,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/14737175.2024.2402058","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T12:58:13Z","timestamp":1726664293000},"page":"1045-1053","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Profiling aducanumab as a treatment option for Alzheimer\u2019s disease: an overview of efficacy, safety and tolerability"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7459-2684","authenticated-orcid":false,"given":"Shreeya","family":"Thussu","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, Division of Geriatrics, Saint Louis University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniketh","family":"Naidu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, Division of Geriatrics, Saint Louis University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu","family":"Manivannan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, Division of Geriatrics, Saint Louis University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, Division of Geriatrics, Saint Louis University School of Medicine, St. Louis, MO, USA"},{"name":"Division of Geriatric Psychiatry, Inaugural Henry &amp; Amelia Nasrallah Endowed, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2019.04.015"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(03)00059-6"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007583"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024539"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01938-w"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01308-6"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_14_1","unstructured":"Association As. Donanemab for treatment of early Alzheimer\u2019s disease \u2014 news pending FDA review. Alzheimer\u2019s Disease and Dementia. 2023. Available from: https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/donanemab\/"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00144-6"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2875"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.227"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_4_20_1","unstructured":"(FDA) FaDA. FDA approves treatment for adults with Alzheimer\u2019s disease. 2024. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24501-0"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01125-y"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.3233\/HAB-160306"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hsr.2022.100039"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2016.06.002"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180802"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12213"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1021792"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12286"},{"key":"e_1_3_4_32_1","volume-title":"FDA grants accelerated approval for Alzheimer\u2019s drug","author":"FDA","year":"2021","unstructured":"FDA. FDA grants accelerated approval for Alzheimer\u2019s drug. FDA Office of Media Affaira. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug."},{"key":"e_1_3_4_33_1","unstructured":"Belluck P Kaplan S Robbins R. How an unproven Alzheimer\u2019s drug got approved. The New York Times. 2021."},{"key":"e_1_3_4_34_1","unstructured":"Block J. Two more FDA advisory panel members resign over Biogen aducanumab approval. J.B. Seeking alpha. 2021. Available from: https:\/\/seekingalpha.com\/news\/3705638-two-more-fda-advisory-panel-members-resign-over-biogen-aducanumab-approval"},{"key":"e_1_3_4_35_1","unstructured":"House DW. FDA advisory committee thumbs down on Biogen Alzheimer\u2019s candidate aducanumab. Seeking alpha. 2020. Available from: https:\/\/seekingalpha.com\/news\/3633299-fda-advisory-committee-thumbs-down-on-biogen-alzheimers-candidate-aducanumab"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00838-z"},{"key":"e_1_3_4_37_1","unstructured":"Hoffman M. Aducanumab approval not recommended by FDA advisory committee. Neurology live. 2020. Available from: https:\/\/www.neurologylive.com\/view\/aducanumab-approval-not-recommended-by-fda-advisory-committee"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100467"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12822"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054367"},{"key":"e_1_3_4_41_1","unstructured":"Biogen. Biogen to realign resources for Alzheimer\u2019s disease franchise. 2024. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-realign-resources-alzheimers-disease-franchise"},{"key":"e_1_3_4_42_1","unstructured":"Lowe D. From one sinking ship to another. Royal society of chemistry. 2024. Available from: https:\/\/www.chemistryworld.com\/opinion\/from-one-sinking-ship-to-another\/4018996.article"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3126"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1424"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.3050"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00197-8"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12377"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3854"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207919"},{"key":"e_1_3_4_52_1","unstructured":"Dunleavy K. 3 more deaths among patients on biogen\u2019s aduhelm fuel safety concerns though no link established: analyst. Fierce pharma. 2022. Available from: https:\/\/www.fiercepharma.com\/pharma\/death-3-more-patients-biogen-s-aduhelm-fuel-more-concern-about-drug-s-safety-though-no-link"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01331-1"},{"key":"e_1_3_4_54_1","unstructured":"Gelman M. Harvard\u2019s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK blasting FDA for \u2018worst drug approval decision in recent U.S. history\u2019. Endpoints news. 2021. Available from: https:\/\/endpts.com\/harvards-aaron-kesselheim-resigns-from-expert-panel-in-wake-of-aducanumab-ok-blasting-fda-for-worst-drug-approval-decision-in-recent-u-s-history\/"},{"key":"e_1_3_4_55_1","unstructured":"Belluck P. Congressional inquiry into Alzheimer\u2019s drug faults its maker and F.D.A. (Ed.^(eds). The New York Times. 2022. Available from: https:\/\/www.nytimes.com\/2022\/2012\/2029\/health\/alzheimers-drug-aduhelm-biogen.html"},{"key":"e_1_3_4_56_1","unstructured":"Aboulenein A. Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer\u2019s drug. Reuters. 2022. Available from: https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/congressional-report-us-fda-broke-own-protocols-approving-biogen-alzheimers-drug-2022-2012-2029\/"},{"key":"e_1_3_4_57_1","unstructured":"O\u2019Brien J. The non-approval of aducanumab in Europe still marks a significant stride forward in dementia research. Join dementia research news. 2021. Available from: https:\/\/news.joindementiaresearch.nihr.ac.uk\/non-approval-aducanumab-europe-still-marks-significant-stride-forward-dementia-research\/"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.5770\/cgj.24.570"},{"key":"e_1_3_4_59_1","unstructured":"FDAnews. Japanese health ministry panel rejects Biogen\u2019s aducanumab. 2021. Available from: https:\/\/www.fdanews.com\/articles\/205910-japanese-health-ministry-panel-rejects-biogens-aducanumab"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108352"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666110-00015"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12944"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.870517"},{"key":"e_1_3_4_64_1","unstructured":"Alzforum. Gantenerumab. Alzforum.org. 2022. Available from: https:\/\/www.alzforum.org\/therapeutics\/gantenerumab"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2024.2402058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T03:39:27Z","timestamp":1729222767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2024.2402058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/14737175.2024.2402058"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2024.2402058","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"value":"1473-7175","type":"print"},{"value":"1744-8360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}